


# UDS & Patient Adherence: A Harm Reduction Approach

Lewis S. Nelson, MD  
Rutgers New Jersey Medical School  
@LNelsonMD  
Lewis.nelson@Rutgers.edu



# No Disclosures

# Workforce drug positivity rates by industry sector



Percentages reflect year-over-year increases between 2015 and 2018. Percent increases have been rounded to the nearest whole number. Classifications are based on the North American Industry Classification System (NAICS). Seventeen of the 20 industry sectors were included in the industry insights; three classifications were excluded from the analysis due to insufficient testing volume.



Quest Diagnostics Drug Testing Index™ 2019  
Media Contact: 1.973.520.2800 | QuestDiagnostics.com/DTI

TEENER

© 1989



"AND THEY SAID WE COULDN'T WIN THE WAR ON DRUGS!"

## *Recreational Marijuana Legalized by New Jersey Voters*

Voters approved a constitutional amendment to legalize cannabis in New Jersey, putting pressure on neighboring states like New York.



New Jersey's legalization of marijuana is expected to generate \$126 million a year, revenue officials say is needed after the pandemic battered the state's finances. Bryan Anselm for The New York Times

By Tracey Tully

Nov. 3, 2020

## Appropriate Use of Drug Testing in Clinical Addiction Medicine

### Expert Panel Members (in alphabetical order)

Louis Baxter, Sr., MD, DFASAM  
Lawrence Brown, MD, MPH, DFASAM  
Matthew Hurford, MD, *Expert Panel Moderator*  
William Jacobs, MD  
Kurt Kleinschmidt, MD  
Marla Kushner, DO, DFASAM  
Lewis Nelson, MD  
Michael Sprintz, DO, FASAM  
Mishka Terplan, MD, MPH, FASAM  
Elizabeth Warner, MD  
Timothy Wiegand, MD, FACMT, FAACT

### ASAM Quality Improvement Council

(in alphabetical order)  
John Femino, MD, DFASAM  
Kenneth Freedman, MD, MS, MBA, DFASAM  
Barbara Herbert, MD, DFASAM  
Margaret Jarvis, MD, DFASAM, *Chair*  
Margaret Kotz, DO, DFASAM

David Pating, MD, FASAM

Sandrine Pirard, MD, PhD, MPH, FAPA, FASAM

Robert Roose, MD, MPH, FASAM

Brendan McEntee, *ASAM Staff*

Penny Mills, MBA, ASAM, *Executive Vice President*

Taleen Safarian, *ASAM Staff*

### Special External Reviewer

Michael Miller, MD, DFASAM, FAPA

### IRETA Team Members (in alphabetical order)

Peter Cohen, MD, *Medical Advisor*  
Leila Giles, BS  
Matthew Hurford, MD, *Expert Panel Moderator*  
Piper Lincoln, MS  
Dawn Lindsay, PhD  
Peter Luongo, PhD  
Jessica Williams, MPH

Disclosure information for the ASAM Expert Panel Members and Quality Improvement Council is available in Appendix 6.

- Testing is not meant to "catch" the patient
- A positive finding suggests need to talk with patient
- Review treatment plan
  - Not to prevent, limit, or change treatment



"You're fired, Jack. The lab results just came back, and you tested positive for Coke."



- Clinical Considerations in Drug Testing
  - Great utility in treatment of substance use disorders because denial is a feature of addiction
  - Testing identifies recent use it does NOT identify addiction or impairment
  - Language regarding the results of the test is important
    - Dirty/clean vs positive/negative

# Screening and Confirmatory Tests




**Screening (Presumptive) Assays – indicate the presumptive presence of drugs**

Highly sensitive  
Rapid, inexpensive  
Cutoff: Yes/No



**Confirmatory (Definitive) Tests – specifically identify the drug detected in the screening assay**

Highly specific  
Complicated, expensive  
Quantitative



# Screening and Confirmatory Tests

- Screening assays:
  - This is all that is done in low-consequence situations
  - Done when confirmatory testing is not practical

02/28/2017 23:09	Amphetamines Urine	N	[Not Detect- ]	Final
Not Detected	* Interpretive Data: Drug Screen results are provided for medical management only. No chain of custody documentation. Testing does not meet NIDA standards. Positive results are not confirmed.			

- Confirmatory testing:
  - Excludes analytical false positives and false negatives
    - Gas Chromatography/Mass Spectrometry
    - Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

# Analytical vs Clinical Interpretation

- Analytical results
  - What the assay finds
- Clinical results
  - What the patient used

# Drugs of Abuse Screening

## NIDA/SAMHSA 5

- Opiates
- Amphetamines
- Cocaine
- Marijuana
- Phencyclidine

## Non-NIDA (Extended)



- Opiates
- Amphetamines
- Cocaine
- Marijuana
- Phencyclidine
- Barbiturates
- Benzodiazepines
- Methadone
- Propoxyphene

# Screening Tests for Drugs of Abuse

- Enzyme immunoassay
  - Based on a substance's structure
  - Relatively inexpensive, easily automated
- Analytical false negatives are less common
- Analytical false positives happen
  - Particularly for amphetamines, almost never for cocaine
  - Confirm positive screens...if the results matter

# Case

- A 30-year-old man presents to a treatment center.
- Urine sent for toxicology assay.
  - a. it returns positive for opioids
  - b. it returns negative for opioids



# The “Opiate” Assay: Not So Good for “Opioids”

	Online DAT opiates II <sup>1</sup> assay	EMIT II+ opiate assay <sup>2</sup>	TDx/TDx- flex opiate assay <sup>3</sup>	Archetict/ AeroSet	AsSym opiate <sup>3</sup>	CEDIA opiate <sup>4</sup>	DRI opiate <sup>4</sup>	DRI oxycodone <sup>4</sup>
Morphine	100	100	100	100	100	100	100	<29
Codeine	134	98	>3.6	167	>3.6	125	167	<20
Ethyl morphine	101		<10		>100			
Diacetyl morphine (heroin)	82					53	86	<33
6-Acetylmorphine	78	69	>20	67	<30	81	79	<200
Dihydrocodeine	69	103	>3.6	106	>3.6	50	67	<100
Morphine-3-glucuronide	54	48	>57	47	>57	81	50	<11
Morphine-6-glucuronide			>5.7		<8.6	47	100	
Hydrocodone	28	121	>8.0	158	>12	48	18	<133
Hydromorphone	21	60	>4.4	54	>6.7	57	7.5	<333
Norcodeine	2							<10
Normorphine							0	<10
Oxycodone	0	12	>1.1	11	<1.7	3.1	1.9	100
Oxymorphone		1.5	<10	0	<15	1.9	0.7	103
Noroxycodone								<0.1
Noroxyphrine								<0.1
Meperidine	0	<0.6	<2.0	0	<3.0	0.2	0	
Levallophan		<4	<6.0	13	<6.0			
Levorphanol		29	>6.0	27	>6.0		2.1	<50
Nalorphine		3	<20	2.3	<30			
Naloxone	0	0.04	<20	0	<30		0	<50
Imiprimine	0					1.6		
Ranitidine						0	0	
Thebaine	25		<20		<30		<15	
Naltrexone	0						0	<20
Fentanyl			<40		<60			



## EMIT Drugs-of-Abuse Urine Assays Cross-Reactivity List

Answers for life.

SIEMENS

# EMIT II Plus

## Cross-Reactivity Guide

Amphetamines .....	4
Barbiturate.....	9
Benzodiazepine .....	13
Cannabinoid .....	17
Cocaine Metabolite.....	21
Ecstasy .....	24
LSD .....	29
Methadone .....	33
Methaqualone.....	36
Opiate.....	40
Phencyclidine .....	44
Propoxyphene.....	48
Absorbance Flags .....	51

### Applicability of Cross-Reactivity Data

The information contained in this Cross-Reactivity List is applicable to any Drugs-of-Abuse Urine Assays that utilize the Siemens Syva® EMIT® II Plus Drugs-of-Abuse Reagents. Siemens analyzers that use these reagents are the ADVIA® 1200/1650/1800/2400, Dimension® RxL/EXL,® Dimension Vista,® and the Vital Viva®/Viva E®/V-Twin®/Viva Jr® chemistry analyzers. The Siemens Syva EMIT II Plus Drugs-of-Abuse assays can also be run on other, non-Siemens clinical chemistry analyzers using Siemens-validated application parameters. These include, but are not limited to, the Beckman Coulter AU® series analyzers, COBAS MIRA series analyzers, and the HITACHI (Roche) 700 and 900 series analyzers.

# Case

- A 21-year-old woman on buprenorphine presents to a treatment clinic.
- UDS: +methadone
- She states she does not use methadone

False Positive (Analytical)

Quetiapine

Olanzapine

Doxylamine

Verapamil

Diphenhydramine

# Interpretation of a True Positive Opiate Screen

- Clinical true positive (patient “misuses” an opioid)

However:

- Unclear which opioid
- Cannot tell time of use or amount used
- Does not correlate with effectiveness or impairment
- Does not indicate route of administration

- Clinical false positive (positive test, not “misusing” opioids)



# Interpretation of a Negative Opiate Screen

- Patient is not using
  - Diversion of pain medicine
- Collection/Lab error
- Wrong assay used
  - e.g.: “Opiate” assay for oxycodone\*
- Cutoffs are often used\*
- Detection periods are short\*

TABLE 2. Length of Time Drugs of Abuse Can Be Detected in Urine

Drug	Time
Alcohol	7-12 h
Amphetamine	48 h
Methamphetamine	48 h
Barbiturate	
Short-acting (eg, pentobarbital)	24 h
Long-acting (eg, phenobarbital)	3 wk
Benzodiazepine	
Short-acting (eg, lorazepam)	3 d
Long-acting (eg, diazepam)	30 d
Cocaine metabolites	2-4 d
Marijuana	
Single use	3 d
Moderate use (4 times/wk)	5-7 d
Daily use	10-15 d
Long-term heavy smoker	>30 d
Opioids	
Codeine	48 h
Heroin (morphine)	48 h
Hydromorphone	2-4 d
Methadone	3 d
Morphine	48-72 h
Oxycodone	2-4 d
Propoxyphene	6-48 h
Phencyclidine	8 d

Data from references 7 through 12.

(\*clinical false negative)

# Matrix considerations

- Window of detection
- Time to obtain results (availability of POCT)
- Ease of collection (need for trained personnel, collection facilities)
- Invasiveness/unpleasantness of collection
- Availability of the sample (e.g., renal health, shy bladder, baldness, dry mouth)
- Susceptibility of the sample to tampering



Drugs and metabolites are concentrated in urine  
Can compare to creatinine



Drugs are found in much lower concentrations  
Easy to observe



Drugs and metabolites incorporated into hair  
Concentrations of drugs low with sporadic use



Prospective collection, 1-2 weeks  
Inter and intraindividual variability




Invasive and expensive to test  
More direct relationship to impairment



Easy to collect and observe  
Essentially limited to ethanol

**TABLE 4.** Comparing Testing Characteristics Across Matrices

	Blood	Breath	Oral Fluid	Urine	Sweat	Hair
General detection period	<24 hours [2] 1–8 hours [25] 1–48 hours [26]	~1 hr per standard drink	<24 hours [2] 12–24 hours [27] 1–36 hours [28] 5–48 hours [29] 12–48 hours [25]	1.5–4 days [29] 1–3 days [25,26,30]	Continuous, usually 1–4 weeks [2,26]	7–90 days [2] 7–100 days [26]
POCT/On-site immunoassay available	Yes, primarily used for alcohol	For alcohol	Yes	Yes	No	No
Primarily detects	Parent drug compound; blood alcohol concentration	Parent drug compound; blood alcohol concentration	Parent drug compound	Drug metabolite	Parent drug compound	Parent drug compound
Best use in treatment setting	Determination of acute impairment or intoxication for alcohol	Determination of acute impairment or intoxication for alcohol	Short-term detection in ongoing treatment	Intermediate-term detection in ongoing treatment	Medium-term prospective monitoring	Long-term monitoring: 3-month drug use history
Ease of collection	Requires staff trained in phlebotomy	Easily collected	Easily collected	Requires specialized collection facility (restroom)	Easily collected	Easily collected
Intrusiveness of collection	High for intravenous access	Low	Low	High	Low	Low
Resistance to tampering	High	High	High, but some uncertainty	Low	High, but some uncertainty	High when chemically untreated
Retesting same sample	Difficult	Generally not possible	Difficult	Possible	Possible depending on patch used	Easy




# Conceptual summary

- Screening vs confirmatory
- Testing results:
  - Analytical: what the assay finds
  - Clinical: what the patient used
- What the results find are one thing
  - What you do with the results are another

We often have questions about choosing testing panels and proper interpretation of results. Where can I get help?

- Medical or analytical toxicologist
- Staff at a clinical or testing laboratory
- A physician with MRO certification





@LNelsonMD  
Lewis.Nelson@Rutgers.edu